POLTREG
PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. Due to positive results of clinical trials of TREG method at the University Clinical Center in Gdansk, sharing this breakthrough therapy with as many patients as possible became the main focus of the company. During nearly two years of preparation prior to company’s establishment, business model, commercialization strategy and legal protection of invention w... ere developed together with the University and research team. In July 2015 company was officially established with the participation of University’s special purpose vehicle (SPV), R&D team – patent creators and implementation team, experienced in securing external funding and managing innovative projects. PolTREG is the only entity entitled to implementing the research findings in the area of T-regulatory lymphocytes and using their growth method for clinical use.
POLTREG
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
Gdansk, Pomorskie, Poland
Country:
Poland
Website Url:
http://www.poltreg.tech
Total Employee:
1+
Status:
Active
Total Funding:
50 K EUR
Technology used in webpage:
IPhone / Mobile Compatible SPF SSL By Default Google Tag Manager Apple Mobile Web Clips Icon Google Analytics Global Site Tag US Privacy User Signal Mechanism Microsoft Exchange Online Office 365 Mail
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Current Employees Featured
Piotr Trzonkowski Co-Founder & CEO @ Poltreg
Co-Founder & CEO
2019-05-01
Małgorzata Mysliwiec Co-Founder @ Poltreg
Co-Founder
Natalia Marek-Trzonkowska Co-Founder @ Poltreg
Co-Founder
Founder
Stock Details
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Poltreg
INNOventure
INNOventure investment in Seed Round - Poltreg
Official Site Inspections
http://www.poltreg.tech
- Host name: static.120.57.181.135.clients.your-server.de
- IP address: 135.181.57.120
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Poltreg"
About us - Poltreg
PolTREG S.A. is a biotechnology company founded in 2015. The headquarters and its laboratories are located in Gdańsk. ... services to third parties to GMP/cGMP standards. TREG …See details»
Poltreg – The future of medicine
PolTREG growth market Treg therapies offer vast commercial potential, with potential peak sales for PTG-007 estimated at $1.9 billion for newly diagnosed T1D. PolTREG S.A. Botaniczna …See details»
Poltreg - Crunchbase Company Profile & Funding
Poltreg was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize the patented TREG method. New. ... poltreg.tech/en/ 228,135; Highlights. …See details»
O Nas - Poltreg
Strategia PolTREG zakłada koncentrację, w tym głównie w zakresie prac badawczo-rozwojowych, na budowie, w oparciu o posiadaną wiedzę i doświadczenie, platformy stanowiącej punkt …See details»
Poltreg - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Organization. Poltreg . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Edit Website Tech Stack by BuiltWith Section. Active …See details»
PolTREG initiates preclinical CAR-Treg development for ...
PolTREG’s CAR-Treg cells are derived using the same technology platform as PTG-007, their lead product, a polyclonal Treg cell therapy. PTG-007 has amassed over a decade of safety …See details»
PolTREG | VentureRadar
Website: http://poltreg.tech/ Develops innovative therapies for autoimmune diseases by increasing the number of T regulatory cells in a patient's body.See details»
PolTREG starts preclinical CAR-Treg development for …
Gdańsk, Poland – 26 September 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune …See details»
PolTREG’s type-1 diabetes Treg cell therapy PTG-007
Jun 24, 2024 PolTREG S.A. Prof Piotr Trzonkowski Chief Executive Officer ir@poltreg.com +48 512 532 401: Investor Relations Frank Hoerning-Andersen Cohesion Bureau +45 25 66 86 02 …See details»
PolTREG - Crunchbase Company Profile & Funding
Technology. Signals & News. Similar Companies. About. PolTREG is a biotechnology company. Gdansk, Pomorskie, Poland; ... PolTREG’s four most advanced projects are already in the …See details»
Projekt PolTREG wybrany przez PARP do dofinansowania
Jan 18, 2025 Projekt PolTREG wybrany przez PARP do dofinansowania. Projekt badawczo-rozwojowy spółki PolTREG został umieszczony przez PARP na liście projektów wybranych do …See details»
PolTREG appoints Dan Shelly, PhD, MBA as Chief Business …
Feb 21, 2024 PolTREG S.A., a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune diseases, announces it has appointed Prof. Daniel Shelly, …See details»
Cell therapy using Tregs in MS headed to Phase 2 trials in Poland
Mar 18, 2024 PolTREG set to manufacture, test Tregs therapy at new facility. MS is an autoimmune condition in which the immune system wrongfully targets and causes damage to …See details»
Empowered Patient Podcast: Personalized T-Regulatory Cell …
Dec 4, 2024. Professor Piotr Trzonkowski, CEO of PolTREG, is focused on developing cell therapies for autoimmune diseases like type-1 diabetes and multiple sclerosis using polyclonal …See details»
Projekt PolTREG wybrany przez ARP do dofinansowania
Jan 18, 2025 Projekt badawczo-rozwojowy spółki PolTREG został umieszczony przez ARP na liście projektów wybranych do dofinansowania - podał PolTREG w komunikacie. Całkowita …See details»
PolTREG starts preclinical CAR-Treg development for
Sep 26, 2024 PolTREG S.A. Prof Piotr Trzonkowski Chief Executive Officer ir@poltreg.com +48 512 532 401: Investor Relations Frank Hoerning-Andersen Cohesion Bureau +45 25 66 86 02 …See details»
PolTREG Treg cell therapy for patients with type-1 diabetes
Sep 9, 2024 PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset …See details»
PolTREG - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Jan 13, 2025 PolTREG is a biotechnology company. Start Free Trial . Chrome ExtensionSee details»
POLTREG S.A. opinie o pracodawcy - Aplikuj.pl
PolTREG S.A. to dynamicznie rozwijająca się firma biotechnologiczna, która od momentu swojego powstania w 2015 roku wyznacza kierunki w dziedzinie terapii komórkowych. Jako …See details»
PolTREG identifies promising efficacy biomarker for Type-1
Apr 4, 2024 PolTREG S.A. Prof Piotr Trzonkowski Chief Executive Officer ir@poltreg.com +48 512 532 401: Investor Relations Chris Maggos Cohesion Bureau +41 79 367 62 54 …See details»